



OPEN ACCESS

APPROVED BY

Alastair George Stewart,
The University of Melbourne, Australia

*CORRESPONDENCE

Frontiers Editorial Office,
✉ research.integrity@frontiersin.org

RECEIVED 22 September 2023

ACCEPTED 22 September 2023

PUBLISHED 28 September 2023

CITATION

Frontiers Editorial Office (2023),
Retraction: Melatonin mediates
osteoblast proliferation through
the STIM1/ORAI1 pathway.
Front. Pharmacol. 14:1299042.
doi: 10.3389/fphar.2023.1299042

COPYRIGHT

© 2023 Frontiers Editorial Office. This is
an open-access article distributed under
the terms of the [Creative Commons
Attribution License \(CC BY\)](#). The use,
distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication
in this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Retraction: Melatonin mediates osteoblast proliferation through the STIM1/ORAI1 pathway

Frontiers Editorial Office*

A Retraction of the Original Research Article

Melatonin mediates osteoblast proliferation through the STIM1/ ORAI1 pathway

by Cao L, Yang K, Yuan W, Zhou S, Zhao R and Qiu S (2022). *Front. Pharmacol.* 13:851663. doi: 10.3389/fphar.2022.851663

The journal retracts the 2022 article cited above.

Following publication, the corresponding author contacted the editorial office stating that there are contributors that have been omitted from the authorship of the published article, despite providing substantial contributions that meet Frontiers authorship criteria. Furthermore, the corresponding author informed the editorial office about errors in data collection that affect the scientific validity of the article. It was found that the concerns were valid and that the article does not meet the standards of editorial and scientific soundness for Frontiers in Pharmacology, therefore, the article has been retracted.

This retraction was approved by the Chief Editors of Frontiers in Pharmacology and the Chief Executive Editor of Frontiers. The authors have agreed to the retraction.